Aldeyra Therapeutics up as drug reduces cough in mid-stage trial

Aldeyra Therapeutics

27/06/2023 13:41

** Shares of biotechnology company Aldeyra Therapeutics
 ALDX.O  up 3.86% at $7.80 premarket 
    ** Co announces "statistically significant" reduction in
cough frequency in mid-stage clinical trial of orally
administered ADX-629 in patients with chronic cough  urn:newsml:reuters.com:*:nBw4YppMsa
    ** Co says ADX-629 was well tolerated and no safety concerns
were identified
    **  Mid-stage clinical trial of ADX-629 in moderate
alcohol-associated hepatitis is expected to initiate in the
second half of 2023 
    ** As of Monday's close, ALDX was up ~8% YTD

 (Reporting by Pritam Biswas in Bengaluru)
 ((Pritam.Biswas@thomsonreuters.com))